By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Are New “Quality of Life Drugs” Worth the Expense?
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > News > Are New “Quality of Life Drugs” Worth the Expense?
NewsSpecialties

Are New “Quality of Life Drugs” Worth the Expense?

Andrew Schorr
Andrew Schorr
Share
4 Min Read
SHARE

Very recently a review committee in the U.K. made a preliminary recommendation that the government’s National Health Service should not pay for a newly approved medicine that greatly reduces or alleviates the symptoms of myelofibrosis (MF). MF develops when there is progressive scarring in the bone marrow that affects one’s ability to make blood cells. Other organs like the spleen and liver try to take over the job and they become enlarged. Along with that, a patient experiences itching, fatigue and weight loss, as well as general malaise and suffering.

Very recently a review committee in the U.K. made a preliminary recommendation that the government’s National Health Service should not pay for a newly approved medicine that greatly reduces or alleviates the symptoms of myelofibrosis (MF). MF develops when there is progressive scarring in the bone marrow that affects one’s ability to make blood cells. Other organs like the spleen and liver try to take over the job and they become enlarged. Along with that, a patient experiences itching, fatigue and weight loss, as well as general malaise and suffering. While a new oral medicine, Jakafi in the U.S. and Jakavi in Europe, has not been proven to reduce or reverse the scarring (fibrosis), most patients feel the drug gives them back a full and productive life. However, it’s very expensive, more than $7,000 a month.

I know all about this personally, since I was officially diagnosed with MF nine months ago and began taking the medicine as symptoms developed last fall. It has worked wonders. I thank my lucky stars that my U.S. private insurance pays for it. It allows me to be productive, support my family and contribute to others. My belief is that the expenditure is worth it not only for me, but for society. By helping me feel good I can work, pay taxes and support others.

The UK panel faces tough choices. Money spent on a “quality of life” drug has to come from somewhere in the health system. I understand that. I also understand these drugs are priced very high to bring a return on investment to the pharmaceutical company, often initially a smaller one that took the risk to develop an important new medicine. In this case, the pre-existing treatments are not very effective.

More Read

Image
More Physicians Entering Primary Care, But Not Enough
New Study Links Infertility to Flame Retardants in Furniture and Carpet
Introducing BioPharma Beat: HealthWorks Collective’s Newest Column
How to Save Money on Diabetes Supplies
5 Surprising Effects Of Dopamine On Your Body To Know About

It would be great if this new drug can be shown in the long run to treat and reverse the underlying disease or significantly lengthen survival. So far there is no evidence for that. Fortunately, other drugs, perhaps used in combination, may lead to that result. But, in the meantime, should the UK, and possibly other government health systems, force patients to suffer when breakthrough medicines exist?

Fortunately, the decision is not final yet and there is a period of comment until June. My hope is the pharmaceutical company, advocates, patients, and the government can all reach a middle ground. Knowing how this “quality of life” drug has allowed me to live a full life, I would hate it if that opportunity is denied to my brothers and sisters in the U.K. or anywhere else.

What are your views on the tough choices for paying for such treatments in these tight economic times?

Wishing you the best of health!

Andrew

TAGGED:cancerpharma
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5kFollowersLike
4.5kFollowersFollow
2.8kFollowersPin
136kSubscribersSubscribe

Latest News

Epidemiological Health Benefits
Personal and Epidemiological Health Benefits of Blood Pressure Management
Health
October 13, 2025
Traumatic Brain Injuries
Understanding Traumatic Brain Injuries: What Families Need to Know
Policy & Law
October 10, 2025
Remote Monitoring touchpoints
Remote Monitoring Touchpoints Patients Will Actually Follow
Technology
October 9, 2025
dental care
Importance of Good Dental Care for Health and Confidence
Dental health Specialties
October 2, 2025

You Might also Like

GeriatricsHome Health

National Adult Day Services Week (September 18-24)

September 19, 2012
virtual reality stroke treatment
Medical DevicesMedical InnovationsSpecialtiesTechnology

Can Stroke Survivors Recover Their Abilities by Controlling Virtual Reality Hands with Their Minds?

November 20, 2013

Remembering When I Last Injected: Timesulin Helps

February 22, 2012
How to Prepare_Doctor_app't
Medical EducationNews

How to Prepare for a Second Opinion Doctor Appointment

November 10, 2015
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2025 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?